Literature DB >> 31582381

Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease.

Jana Travnickova1,2, Sonia Wojciechowska1,2, Ava Khamseh1,3, Philippe Gautier1, Daniel V Brown4,5, Thomas Lefevre4, Alessandro Brombin1,2, Ailith Ewing1, Amy Capper1,2, Michaela Spitzer6, Ramile Dilshat7, Colin A Semple1, Marie E Mathers8, James A Lister9, Eiríkur Steingrimsson7, Thierry Voet4,10, Chris P Ponting1, E Elizabeth Patton11,2.   

Abstract

The melanocyte-inducing transcription factor (MITF)-low melanoma transcriptional signature is predictive of poor outcomes for patients, but little is known about its biological significance, and animal models are lacking. Here, we used zebrafish genetic models with low activity of Mitfa (MITF-low) and established that the MITF-low state is causal of melanoma progression and a predictor of melanoma biological subtype. MITF-low zebrafish melanomas resembled human MITF-low melanomas and were enriched for stem and invasive (mesenchymal) gene signatures. MITF-low activity coupled with a p53 mutation was sufficient to promote superficial growth melanomas, whereas BRAFV600E accelerated MITF-low melanoma onset and further promoted the development of MITF-high nodular growth melanomas. Genetic inhibition of MITF activity led to rapid regression; recurrence occurred following reactivation of MITF. At the regression site, there was minimal residual disease that was resistant to loss of MITF activity (termed MITF-independent cells) with very low-to-no MITF activity or protein. Transcriptomic analysis of MITF-independent residual disease showed enrichment of mesenchymal and neural crest stem cell signatures similar to human therapy-resistant melanomas. Single-cell RNA sequencing revealed MITF-independent residual disease was heterogeneous depending on melanoma subtype. Further, there was a shared subpopulation of residual disease cells that was enriched for a neural crest G0-like state that preexisted in the primary tumor and remained present in recurring melanomas. These findings suggest that invasive and stem-like programs coupled with cellular heterogeneity contribute to poor outcomes for MITF-low melanoma patients and that MITF-independent subpopulations are an important therapeutic target to achieve long-term survival outcomes. SIGNIFICANCE: This study provides a useful model for MITF-low melanomas and MITF-independent cell populations that can be used to study the mechanisms that drive these tumors as well as identify potential therapeutic options.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/22/5769/F1.large.jpg. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31582381      PMCID: PMC7116150          DOI: 10.1158/0008-5472.CAN-19-0037

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Asymmetric cancer cell division regulated by AKT.

Authors:  Ipsita Dey-Guha; Anita Wolfer; Albert C Yeh; John G Albeck; Revati Darp; Eduardo Leon; Julia Wulfkuhle; Emanuel F Petricoin; Ben S Wittner; Sridhar Ramaswamy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-14       Impact factor: 11.205

2.  JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers.

Authors:  Nicole D Facompre; Kayla M Harmeyer; Xavier Sole; Sheheryar Kabraji; Zachary Belden; Varun Sahu; Kelly Whelan; Koji Tanaka; Gregory S Weinstein; Kathleen T Montone; Alexander Roesch; Phyllis A Gimotty; Meenhard Herlyn; Anil K Rustgi; Hiroshi Nakagawa; Sridhar Ramaswamy; Devraj Basu
Journal:  Cancer Res       Date:  2016-08-03       Impact factor: 12.701

3.  A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor.

Authors:  Aaron T L Lun; Davis J McCarthy; John C Marioni
Journal:  F1000Res       Date:  2016-08-31

Review 4.  BRN2, a POUerful driver of melanoma phenotype switching and metastasis.

Authors:  Mitchell E Fane; Yash Chhabra; Aaron G Smith; Richard A Sturm
Journal:  Pigment Cell Melanoma Res       Date:  2018-06-05       Impact factor: 4.693

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  mitfa is required at multiple stages of melanocyte differentiation but not to establish the melanocyte stem cell.

Authors:  Stephen L Johnson; Anhthu N Nguyen; James A Lister
Journal:  Dev Biol       Date:  2010-12-10       Impact factor: 3.582

7.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

8.  Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Authors:  Judith Müller; Oscar Krijgsman; Jennifer Tsoi; Lidia Robert; Willy Hugo; Chunying Song; Xiangju Kong; Patricia A Possik; Paulien D M Cornelissen-Steijger; Marnix H Geukes Foppen; Kristel Kemper; Colin R Goding; Ultan McDermott; Christian Blank; John Haanen; Thomas G Graeber; Antoni Ribas; Roger S Lo; Daniel S Peeper
Journal:  Nat Commun       Date:  2014-12-15       Impact factor: 14.919

9.  BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

Authors:  E Elizabeth Patton; Hans R Widlund; Jeffery L Kutok; Kamden R Kopani; James F Amatruda; Ryan D Murphey; Stephane Berghmans; Elizabeth A Mayhall; David Traver; Christopher D M Fletcher; Jon C Aster; Scott R Granter; A Thomas Look; Charles Lee; David E Fisher; Leonard I Zon
Journal:  Curr Biol       Date:  2005-02-08       Impact factor: 10.834

10.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

View more
  16 in total

1.  Fate mapping melanoma persister cells through regression and into recurrent disease in adult zebrafish.

Authors:  Jana Travnickova; Sarah Muise; Sonia Wojciechowska; Alessandro Brombin; Zhiqiang Zeng; Adelaide I J Young; Cameron Wyatt; E Elizabeth Patton
Journal:  Dis Model Mech       Date:  2022-09-16       Impact factor: 5.732

Review 2.  Heterogeneity in Melanoma.

Authors:  Mei Fong Ng; Jacinta L Simmons; Glen M Boyle
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

Review 3.  The Zebrafish model in dermatology: an update for clinicians.

Authors:  Irene Russo; Emma Sartor; Laura Fagotto; Natascia Tiso; Mauro Alaibac; Anna Colombo
Journal:  Discov Oncol       Date:  2022-06-17

4.  Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.

Authors:  Chewei Anderson Chang; Jayu Jen; Shaowen Jiang; Azin Sayad; Arvind Singh Mer; Kevin R Brown; Allison M L Nixon; Avantika Dhabaria; Kwan Ho Tang; David Venet; Christos Sotiriou; Jiehui Deng; Kwok-Kin Wong; Sylvia Adams; Peter Meyn; Adriana Heguy; Jane A Skok; Aristotelis Tsirigos; Beatrix Ueberheide; Jason Moffat; Abhyudai Singh; Benjamin Haibe-Kains; Alireza Khodadadi-Jamayran; Benjamin G Neel
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

5.  The Stress-Like Cancer Cell State Is a Consistent Component of Tumorigenesis.

Authors:  Maayan Baron; Mohita Tagore; Miranda V Hunter; Isabella S Kim; Reuben Moncada; Yun Yan; Nathaniel R Campbell; Richard M White; Itai Yanai
Journal:  Cell Syst       Date:  2020-09-09       Impact factor: 10.304

Review 6.  Melanoma models for the next generation of therapies.

Authors:  E Elizabeth Patton; Kristen L Mueller; David J Adams; Niroshana Anandasabapathy; Andrew E Aplin; Corine Bertolotto; Marcus Bosenberg; Craig J Ceol; Christin E Burd; Ping Chi; Meenhard Herlyn; Sheri L Holmen; Florian A Karreth; Charles K Kaufman; Shaheen Khan; Sebastian Kobold; Eleonora Leucci; Carmit Levy; David B Lombard; Amanda W Lund; Kerrie L Marie; Jean-Christophe Marine; Richard Marais; Martin McMahon; Carla Daniela Robles-Espinoza; Ze'ev A Ronai; Yardena Samuels; Maria S Soengas; Jessie Villanueva; Ashani T Weeraratna; Richard M White; Iwei Yeh; Jiyue Zhu; Leonard I Zon; Marc S Hurlbert; Glenn Merlino
Journal:  Cancer Cell       Date:  2021-02-04       Impact factor: 31.743

7.  Long-term non-invasive drug treatments in adult zebrafish that lead to melanoma drug resistance.

Authors:  Yuting Lu; E Elizabeth Patton
Journal:  Dis Model Mech       Date:  2022-05-09       Impact factor: 5.732

Review 8.  From Tank to Treatment: Modeling Melanoma in Zebrafish.

Authors:  William Tyler Frantz; Craig J Ceol
Journal:  Cells       Date:  2020-05-22       Impact factor: 6.600

9.  MITF reprograms the extracellular matrix and focal adhesion in melanoma.

Authors:  Ramile Dilshat; Valerie Fock; Colin Kenny; Ilse Gerritsen; Romain Maurice Jacques Lasseur; Jana Travnickova; Ossia M Eichhoff; Philipp Cerny; Katrin Möller; Sara Sigurbjörnsdóttir; Kritika Kirty; Berglind Ósk Einarsdottir; Phil F Cheng; Mitchell Levesque; Robert A Cornell; E Elizabeth Patton; Lionel Larue; Marie de Tayrac; Erna Magnúsdóttir; Margrét Helga Ögmundsdóttir; Eirikur Steingrimsson
Journal:  Elife       Date:  2021-01-13       Impact factor: 8.140

Review 10.  Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials.

Authors:  E Elizabeth Patton; Leonard I Zon; David M Langenau
Journal:  Nat Rev Drug Discov       Date:  2021-06-11       Impact factor: 112.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.